ClearPoint Neuro, Inc. Annual report pursuant to Section 13 and 15(d)

Annual report pursuant to Section 13 and 15(d)

Note 5 - Sale of Intellectual Property in Exchange for Cancellation of the Boston Scientific Notes (Details)

Note 5 - Sale of Intellectual Property in Exchange for Cancellation of the Boston Scientific Notes (Details) (USD $)	12 Months Ended			1 Months Ended
	Dec. 31, 2013	Dec. 31, 2014	Dec. 31, 2008	Mar. 31, 2014
Note 5 - Sale of Intellectual Property in Exchange for Cancellation of the Boston Scientific Notes (Details) [Line Items]
Number of Convertible Notes Payable Cancelled				3
Revenue from Related Parties	$ 650,000us-gaap_RevenueFromRelatedParties
BSC Cardiac Agreement [Member]
Note 5 - Sale of Intellectual Property in Exchange for Cancellation of the Boston Scientific Notes (Details) [Line Items]
Revenue from Related Parties			13,000,000
Related Party Transaction Deferred Revenue Recognition Period		5 years
Boston Scientific Notes [Member]
Note 5 - Sale of Intellectual Property in Exchange for Cancellation of the Boston Scientific Notes (Details) [Line Items]
Sale of Intangible Asset				4,338,601
Notes Payable Cancelled, Principal Amount				$ 4,338,601

- Definition

Amount of revenue, fees and commissions earned from transactions between (a) a parent company and its subsidiaries; (b) subsidiaries of a common parent; (c) an entity and trusts for the benefit of employees, for example, but not limited to, pension and profit-sharing trusts that are managed by or under the trusteeship of the entity's management; (d) an entity and its principal, owners, management, or members of their immediate families; and (e) affiliates.

+ References + Details